Our Story

MedDay is a biotechnology company developing new drugs targeting brain metabolism to treat diseases of the nervous system. Learn more about MedDay's story.

Read More

Our Products

MedDay currently has molecules in development for treatment of multiple sclerosis, autism and Alzheimer’s disease.

Read More

Our Vision

MedDay addresses areas of unmet need in neurological and psychiatric diseases through the brain metabolism. This approach relies on unique clinical and pharmaceutical development expertise in the field of rare inborn errors of metabolism.

Read More

MedDay SA au capital de 116 660 €
Siège social : 96 Boulevard Haussmann 75008 Paris
RCS PARIS 534 957 865
Publication Director : Dr Frédéric Sedel